FDA Examining BLAs To Counter Smallpox Vaccine's Side Effects Aug. 4, 2004 By Karen Carey No Comments
Santarus Gets $57M In Follow-On Following Approval Of Rapinex July 26, 2004 By Karen Carey No Comments
Alexion Moving Eculizumab Into Phase III After SPA OK July 21, 2004 By Karen Carey No Comments Completing a special protocol assessment process with the FDA, Alexion Pharmaceuticals Inc. plans to begin a Phase III program of eculizumab for the chronic orphan blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). (BioWorld Today)Read More
